NRSN
NASDAQ · Biotechnology
Neurosense Therapeutics Ltd
$0.94
+0.07 (+8.03%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.58M | 1.62M | 1.28M |
| Net Income | 134.3K | 163.7K | 131.8K |
| EPS | — | — | — |
| Profit Margin | 8.5% | 10.1% | 10.3% |
| Rev Growth | +15.5% | +19.0% | +13.7% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 1.76M | 1.65M | 1.88M |
| Total Equity | 9.24M | 9.14M | 9.98M |
| D/E Ratio | 0.19 | 0.18 | 0.19 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 233.3K | 224.5K | 177.5K |
| Free Cash Flow | 149.0K | 201.8K | 175.9K |